This study aimed to assess the prevalence of developmental venous anomaly (DVA) in
patients with thalamic glioma. Furthermore, we explored the association between DVA
and some important biomarkers, such as IDH1 mutation, and H3K27M mutation.
Patients and Methods
Patients who received tumor resection in West China Hospital between August 2009 and
October 2017 were enrolled. Propensity score matching was conducted based on a logistic
regression model and 1:1 matching for case and control was used to generate a new
cohort from patients with meningioma. Chi-square test, t-test, univariate and multivariate analyses were employed to assess the prevalence
of DVA in thalamic glioma and meningioma and to identify risk factors associated with
Ninety-nine patients with thalamic glioma were enrolled in the current study (male,
n = 54; female, n = 45). The mean age was 42.9 ± 15.3 years old. We identified a higher
prevalence of DVA in 99 patients with thalamic glioma when compared with 99 patients
with meningioma (18.18% vs. 7.07%), which was slightly lower than the prevalence of DVA in glioma reported in
previous studies. Furthermore, the distribution of gender, age, and tumor grade in
DVA did not reach statistical significance. Chi-square test, univariate and multivariate
analyses showed that IDH1 mutation, ATRX mutation, MGMT promoter methylation, p53
mutation, MMP9, EGFR, and Top II positive expression, TERT mutation, and H3K27M mutation
were not associated with the development of DVA in thalamic glioma.
A higher prevalence of DVA was found in thalamic glioma compared with meningioma.